A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (NCT05242471)

🧪 Interventions in This Study

• Guselkumab (BIOLOGICAL)
• Golimumab (BIOLOGICAL)
• JNJ-78934804 (BIOLOGICAL)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (456 Sites)

Showing the first 25 of 456 sites.

• University of Alabama Liver Center — Birmingham, Alabama
• Del Sol Research Management, LLC — Tucson, Arizona
• Moore Clinical Trials, LLC — Little Rock, Arkansas
• Om Research LLC — Apple Valley, California
• Valley Gastroenterology Medical Group — Arcadia, California
• Southern California Research Center — Coronado, California
• Desert Gastroenterology Associates — Lancaster, California
• Cedars Sinai Medical Center — Los Angeles, California
• UCLA — Los Angeles, California
• Hoag Memorial Hospital — Newport Beach, California
• UCI Irvine Medical Center — Orange, California
• Medical Associates Research Group, Inc. — San Diego, California
• University of California San Francisco — San Francisco, California
• University of Colorado — Aurora, Colorado
• Medical Research Center of Connecticut — Hamden, Connecticut
• Yale University School Of Medicine — New Haven, Connecticut
• MedStar Georgetown University Hospital — Washington D.C., District of Columbia
• Pioneer Research Solutions Inc. — Coconut Creek, Florida
• Homestead Associates in Research Inc — Homestead, Florida
• Osceola Mental Health D/B/A Park Place Behavioral Health Care — Kissimmee, Florida
• Florida Research Center Inc. — Lakewood Rch, Florida
• University of Miami Hospital — Miami, Florida
• Gastroenterology Group Of Naples — Naples, Florida
• Omega Research Consultants — Orlando, Florida
• Synergy Clinical Research — St. Petersburg, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Crohn's Disease

• A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) — Birmingham, Alabama
• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Sun City, Arizona
• Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. — Blacktown, New South Wales
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — San Francisco, California
• Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis — Boston, Massachusetts

Explore by condition: All Crohn's Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.